Format

Send to

Choose Destination
Biologicals. 2014 Sep;42(5):223-36. doi: 10.1016/j.biologicals.2014.07.003. Epub 2014 Aug 16.

Adventitious agents in viral vaccines: lessons learned from 4 case studies.

Author information

1
IABS, POB 1925, Palm Springs, CA 92263, USA. Electronic address: petriccianiIABS@aol.com.
2
Grimalkin Partners, 13401 Norden Drive, Silver Spring, MD 20906, USA. Electronic address: rsheets@grimalkinpartners.com.
3
3 The Farthings, Kingston Upon Thames, Surrey KT2 7PT, UK. Electronic address: elwyn.griffiths2011@btinternet.com.
4
Group Lead, Norms and Standards for Biologicals, Department of Essential Medicines and Health Products (EMP) Health Systems and Innovation (HIS) Cluster, WHO L276, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: knezevici@who.int.

Abstract

Since the earliest days of biological product manufacture, there have been a number of instances where laboratory studies provided evidence for the presence of adventitious agents in a marketed product. Lessons learned from such events can be used to strengthen regulatory preparedness for the future. We have therefore selected four instances where an adventitious agent, or a signal suggesting the presence of an agent, was found in a viral vaccine, and have developed a case study for each. The four cases are: a) SV40 in polio vaccines; b) bacteriophage in measles and polio vaccines; c) reverse transcriptase in measles and mumps vaccines; and d) porcine circovirus and porcine circovirus DNA sequences in rotavirus vaccines. The lessons learned from each event are discussed. Based in part on those experiences, certain scientific principles have been identified by WHO that should be considered in regulatory risk evaluation if an adventitious agent is found in a marketed vaccine in the future.

KEYWORDS:

Adventitious agents; Regulatory preparedness; Vaccines; Viral contamination

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center